Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | EEF2K | O00418 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7700500 | 1.00 | PTGS2 (0.52) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8784131 | 0.90 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8784134 | 0.90 | PTGS2 (0.50) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8897231 | 0.90 | PTGS2 (0.52) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8992117 | 0.90 | PTGS2 (0.52) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL9304376 | 0.89 | PTGS2 (0.51) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL9304372 | 0.89 | PTGS2 (0.51) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8779600 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8779594 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 | |
| SCHEMBL8532777 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1CYP1A2CYP2C9ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420428-B1 | TREATING HEPATITIS C AND HEPATIC FIBROSIS USING 2,6-DI-TERT-BUTYLPHENOL DERIVATIVES; EFFECTIVE IN SUBJECTS WITH INTERFERON INSUSCEPTIBILITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-07-16 | — | — | US | disclosed |
| US-6369097-B1 | Treatment and prevention of hepatic disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| US-6348493-B1 | TREATMENT OF HEPATITIS C BY ADMINISTERING 2,6-DI-TER-BUTYLPHENOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-02-19 | — | — | US | disclosed |
| US-6218437-B1 | ADMINISTERING A THERAPEUTIC AMOUNT OF DI-TERT-BUTYLPHENOL DERIVATIVE TO SUBJECT UNDER CONDITIONS SUCH THAT SAID SYMPTOMS ARE DIMINISHED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-04-17 | — | — | US | disclosed |
| WO-2001021166-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | disclosed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5731336-A | USING ARYL-SUBSTITUTED RHODAMINES | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5691367-A | ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | ELI LILLY AND COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |